icon star paper   Articles  
Back grey_arrow_rt.gif
New Restrictions in ADAP Programs
  This report was distributed yesterday by NASTAD:
NATIONAL ALLIANCE OF STATE AND TERRITORIAL AIDS DIRECTORS. NASTAD is a Washington DC based group that represents the state ADAP programs and the directors of these programs.
Congress & the Administration did not grant requests from the ADAP Working Group and others for additional funding to meet the needs and costs of providing adequate access through ADAP programs. Several large drug companies have announced they would freeze ADAP prices for HIV drugs in response to this problem: notably Pfizer (Agouron), GlaxoSmithKline, Abbott, Bristol Myers. You can help by contacting your state officials, congressional representatives, and senators, and expressing your concerns and asking them to do something about this problem.
FY2002 ADAP Funding Watch
Due to insufficient resources in FY2001 and projected deficits in FY2002, 10 ADAPs have already closed enrollment to new clients or limited access to antiretroviral treatments (ARVs). In addition, a number of jurisdictions with currently fiscally stable ADAPs (e.g. Florida and New York) report the potential need to implement ADAP restrictions based on current funding levels and projected trends in program utilization.
ADAPs with waiting lists, client expenditure caps and/or drug access restrictions
Maine (ARV restrictions)
North Carolina
South Dakota
Texas (ARV restrictions)
ADAPs provide life saving HIV treatments to low income, uninsured individuals living with HIV/AIDS in all 50 states, the District of Columbia, the Commonwealth of Puerto Rico, the U.S. Virgin Islands and Guam. Federal funding for ADAPs in FY2001 and FY2002 did not meet the needs specified by state and territorial AIDS programs and is expected to lead to wide spread ADAP access restrictions in FY2002. The Administration's FY2003 proposed budget includes no increase in federal funding for ADAPs-even to address annual inflationary costs.
It was also reported that Mississippi and New York may institute restrictions.
The shortfall in ADAP funding raises concerns about how HCV/HIV coinfected patients who currently receive access to HIV therapy through ADAP will access HCV therapy.
Jules Levin
National AIDS Treatment Advocacy Project
  icon paper stack View Older Articles   Back to Top   www.natap.org